 Maxim Group reiterated their buy rating on shares of ContraFect NASDAQ:CFRX in a research note published on Thursday morning, AnalystRatings.com reports. The firm currently has a 22.00 target price on the biotechnology companys stock. Other research analysts have also issued research reports about the stock. Chardan Capital reiterated a buy rating and issued a 15.00 ... 